Blog
RSS FeedPosted by Michael Wonder on 17 Nov 2022
Targeted treatment for rare form of aggressive lung cancer gets NICE approval
16 November 2022 - Mobocertinib recommended as a treatment for a rare and aggressive form of lung cancer. ...
Posted by Michael Wonder on 16 Nov 2022
Ruxolitinib phosphate for the treatment of patients with acute graft versus host disease that is refractory to the use of corticosteroids
16 November 2022 - NICE is unable to make a recommendation about the use in the NHS of ruxolitinib phosphate for ...
Posted by Michael Wonder on 11 Nov 2022
Cannabidiol for the treatment of patients with seizures caused by tuberous sclerosis complex
8 November 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 10 Nov 2022
Olaparib for adjuvant treatment of patients with high risk, HER2 negative, BRCA positive early breast cancer after chemotherapy
10 November 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 08 Nov 2022
NICE final draft guidance adds further treatment option for triple negative breast cancer
8 November 2022 - NICE has today published final draft guidance which recommends pembrolizumab as an option for people with ...
Posted by Michael Wonder on 06 Nov 2022
Bulevirtide acetate for the treatment of patients with chronic hepatitis D
4 November 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 02 Nov 2022
Slow-release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis
2 November 2022 - NICE is unable to make a recommendation on slow-release potassium bicarbonate–potassium citrate (Sibnayal) for treating distal renal ...
Posted by Michael Wonder on 23 Oct 2022
Could more medicines be recommended for routine commissioning rather than spending time in the Cancer Drugs Fund?
19 October 2022 - A new analysis commissioned by the ABPI suggests they could. ...
Posted by Michael Wonder on 19 Oct 2022
Fostamatinib disodium hexahydrate for the treatment of patients with refractory chronic immune thrombocytopenia
19 October 2022 - NICE has published evidence-based recommendations on the use of fostamatinib disodium hexahydrate for the treatment of ...
Posted by Michael Wonder on 19 Oct 2022
Zanubrutinib for the treatment of patients with Waldenström’s macroglobulinaemia
19 October 2022 - NICE has published evidence-based recommendations on the use of zanubrutinib for the treatment of adults with ...
Posted by Michael Wonder on 19 Oct 2022
Oestradiol hemifumarate with norethisterone acetate and relugolix for the treatment of moderate to severe symptoms of uterine fibroids
19 October 2022 - NICE has published evidence based recommendations on the use of oestradiol hemifumarate with norethisterone acetate and ...
Posted by Michael Wonder on 19 Oct 2022
Pembrolizumab for adjuvant treatment of adults with renal cell carcinoma
19 October 2022 - NICE has published evidence-based recommendations on the use of pembrolizumab for the adjuvant treatment of adults ...
Posted by Michael Wonder on 12 Oct 2022
SQ HDM SLIT for the treatment of patients with allergic rhinitis and allergic asthma caused by house dust mites
12 October 2022 - NICE is unable to make a recommendation on the use of SQ HDM SLIT (Acarizax) for the ...
Posted by Michael Wonder on 12 Oct 2022
Lutetium Lu 177 vipivotide tetraxetan for treating PSMA positive hormone relapsed metastatic prostate cancer after two or more therapies
12 October 2022 - The Department of Health and Social Care has asked the NICE to produce guidance on using ...
Posted by Michael Wonder on 12 Oct 2022
NICE partners with international health technology assessment bodies to boost collaboration on shared opportunities and challenges
12 October 2022 - Six health technology assessment bodies from three continents are to collaborate on a range of topics that ...